Nirogy Therapeutics to Present at AACR Annual Meeting 2021
BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- Nirogy Therapeutics Inc., a privately-held biotechnology company developing novel small molecules to target cellular transporters, today announced that the company will present two e-posters at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting, which is being held on April 10-15, 2021 and May 17-21, 2021.
Nirogy will highlight preliminary data that shows that NGY-B, the company’s first-in-class, orally bioavailable small molecule inhibitor, intervenes in two key hallmarks of cancer, metabolism and immunity, providing a potential novel therapeutic modality to combat triple-negative breast cancer (TNBC). Nirogy will also highlight preclinical data that demonstrate the potential of NGY-B to inhibit melanoma by targeting metabolic symbiosis and activating antitumor immune response mechanisms.
“We’re thrilled to be presenting two impactful posters at this year’s AACR virtual conference,” said Vincent Sandanayaka, Ph.D., founder, president and chief executive officer of Nirogy. “These preliminary data show that NGY-B has significant efficacy in ‘immunologically cold’ mouse tumor models, where many drugs fail. We’re also pleased with our findings that NGY-B works synergistically with anti-CTLA4 checkpoint inhibitors, suggesting a potential future combination therapy for patients. We look forward to continuing to evalute NGY-B as we move closer to the clinic.”
Poster Presentation Details:
Title: Dual MCT1/4 inhibition promotes anti-tumor immunity in triple-negative breast cancer
Title: A novel treatment approach for melanoma by dually targeting MCT1 and MCT4 lactate transporters
For more information, please access the abstracts online here.
For more information, please visit nirogytx.com.
IDEA Showcase Startup Pitch Event & Reception
Conference Sessions (Full conference pass required)